OMERACTOutcome Measures in Rheumatoid Arthritis Clinical Trials
References in periodicals archive ?
Maarten Boers, a member of the OMERACT executive committee, said at a rheumatology course sponsored by New York University.
Although patients were involved in developing the remission definition by OMERACT, that dimension wasn't fully studied.
Since our aim was to determine presence versus absence of pathology without attempting to quantify its severity, scoring for synovitis and erosions according to the OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies system was not performed.
Testing of the OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage in rheumatoid arthritis: a systematic literature search on 5 candidate biomarkers.
Regarding this last concern, the adoption of standard methods for scan acquisition (17) and the use of consensus definitions of erosions and synovitis developed by the OMERACT (Outcome Measures in Rheumatoid Arthritis Clinical Trials) group (18) may help overcome these obstacles.
Meanwhile, an ultrasound task force within the Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) continues to work on the development of a Global OMERACT Sonography Scoring (GLOSS) system for RA.
Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondylo arthritis: the OMERACT 9 v2 criteria.
The committee followed the framework of the OMERACT (Outcome Measures in Rheumatology) Filter that requires all measures to be truthful, discriminative, and feasible in their intended setting.
OMERACT (Outcome Measures in Rheumatology) is linked to the Cochrane Musculoskeletal Group (CMSG), one of the international groups of The Cochrane Collaboration, where the outcomes endorsed by OMERACT, based on truth, discrimination, and feasibility (OMERACT filter), are recommended for use in systematic reviews of interventions for musculoskeletal conditions.
The GRAPPA group, working within the context of an OMERACT workshop (18) and module, (19,20) has developed a core set of domains that should be assessed in all PsA clinical trials and in long-term registry studies (Fig.